Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years

Siponimod significantly reduced the risk of confirmed disability progression (CDP), worsening in cognitive processing speed (CPS), relapses, and magnetic resonance imaging (MRI) measures of brain atrophy and inflammation versus placebo in secondary progressive multiple sclerosis (SPMS) patients in t...

Celý popis

Podrobná bibliografie

Vydáno v:	Multiple sclerosis Ročník 28; číslo 10; s. 1591
Hlavní autoři:	Cree, Bruce Ac, Arnold, Douglas L, Fox, Robert J, Gold, Ralf, Vermersch, Patrick, Benedict, Ralph Hb, Bar-Or, Amit, Piani-Meier, Daniela, Rouyrre, Nicolas, Ritter, Shannon, Kilaru, Ajay, Karlsson, Goeril, Giovannoni, Gavin, Kappos, Ludwig
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 01.09.2022
Témata:	Atrophy Azetidines Benzyl Compounds Humans Multiple Sclerosis - drug therapy Multiple Sclerosis, Chronic Progressive - drug therapy Multiple Sclerosis, Relapsing-Remitting - drug therapy Recurrence confirmed cognitive worsening cortical gray matter S1P modulator secondary progressive multiple sclerosis Confirmed disability progression siponimod
ISSN:	1477-0970, 1477-0970
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!